粪菌移植治疗非酒精性脂肪性肝病研究与思考

doi:10.3969/j.issn.1672-5069.2017.06.002

摘要/Abstract

骆庆玲, 周永健. 粪菌移植治疗非酒精性脂肪性肝病研究与思考[J]. 实用肝脏病杂志, 2017, 20(6): 647-650.

Luo Qinglin, Zhou Yongjian. Fecal microbiota transplantation in the treatment of patients with non-alcoholic fatty liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(6): 647-650.

[1] Eiseman B,Silen W,Bascom G S,et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery,1958,44（5）:854-859.
[2] Rossen N G,Macdonald J K,de Vries E M,et al. Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review. World J Gastroenterol,2015,21（17）:5359-5371.
[3] Lonardo A,Bellentani S,Argo CK,et al. Epidemiological modifiers of non-alcoholic fatty liver disease:Focus on high-risk groups. Dig Liver Dis,2015,47（12）:997-1006.
[4] 周永健,聂玉强,李瑜元,等. 广东省成人代谢综合征与非酒精性脂肪肝患病的关系. 胃肠病学和肝病学杂志,2008,17（8）:647-649.
[5] Ampuero J,Ranchal I,Gallego-Duran R,et al. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients. J Gastroenterol Hepatol,2016,31（9）:1611-1618.
[6] Rinella ME. Nonalcoholic fatty liver disease:a systematic review. JAMA,2015,313（22）:2263-2273.
[7] Sepideh A,Karim P,Hossein A,et al. Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease:A double-blind randomized clinical trial. J Am Coll Nutr,2016,35（6）:500-505.
[8] Le Roy T,Llopis M,Lepage P,et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut,2013,62（12）:1787-1794.
[9] Graoph H. Structure,function and diversity of the healthy human microbiome. Nature,2012,486（7402）:207-214.
[10] Ridaura VK,Faith JJ,Rey FE et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science,2013,341（6150）:1241214.
[11] Turnbaugh PJ,Ley RE,Mahowald MA,et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature,2006,444（7122）:1027-1031.
[12] Zhou D,Pan Q,Shen F,et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep,2017,7（1）:1529.
[13] Michail S,Lin M,Frey MR,et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol,2014,91（2）:1-9.
[14] Spencer MD,Hamp TJ,Reid RW,et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology,2011,140（3）:976-986.
[15] Zhu L,Baker SS,Gill C,et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis（NASH） patients:a connection between endogenous alcohol and NASH. Hepatology,2013,57（2）:601-609.
[16] Wong VW,Tse CH,Lam TT,et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis-a longitudinal study. PLoS One,2013,8（4）:e62885.
[17] Miele L,Valenza V,La Torre G,et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology,2009,49（6）:1877-1887.
[18] Gabele E,Dostert K,Hofmann C,et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol,2011,55（6）:1391-1399.
[19] 蔡冰,周永健,李瑜元,等. 脂联素基因启动子区甲基化状态对大鼠实验性非酒精性脂肪性肝病的影响. 临床和实验医学杂志,2015,15（3）:169-173.
[20] Maslowski KM,Vieira AT,Ng A,et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature,2009,461（7268）:1282-1286.
[21] Volynets V,Kuper MA,Strahl S,et al. Nutrition,intestinal permeability,and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease （NAFLD）. Dig Dis Sci,2012,57（7）:1932-1941.
[22] Jiang C,Xie C,Lyu Y,et al. Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction. Nat Communicat,2015,6:10166.
[23] Houten SM,Volle DH,Cummins CL,et al. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue. Mol Endocrinol,2007,21（6）:1312-1323.
[24] Wei Y,Gong J,Zhu W,et al. Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. BMC Microbiol,2016,16（1）:255.
[25] Kelly CR,Kahn S,Kashyap P,et al. Update on fecal microbiota transplantation 2015:Indications,methodologies,mechanisms,and Outlook. Gastroenterology,2015,149（1）:223-237.
[26] Rossen NG. Fecal microbiota transplantation as novel therapy in gastroenterology:A systematic review. World J Gastroenterol,2015,21（17）:5359.
[27] Rubin DT. Fecal microbiota transplantation for the treatment of inflammatory bowel disease. Gastroenterol Hepatol （NY）,2015,11（9）:618-620.
[28] Wang S,Xu M,Wang W,et al. Systematic review:Adverse events of fecal microbiota transplantation. PLoS One,2016,11（8）:e161174.

粪菌移植治疗非酒精性脂肪性肝病研究与思考

Fecal microbiota transplantation in the treatment of patients with non-alcoholic fatty liver diseases

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	任俞霏, 陈小青, 孔维宗, 王迎春. 丹酚酸B对非酒精性脂肪性肝病细胞模型自噬功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 804-807.
[2]	李颖怡, 郭翠芬, 章瑞南, 汪保灿, 潘勤, 汪余勤, 曹海霞, 范建高. ALDH2 rs671基因多态性与非酒精性脂肪性肝病相关性研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 848-851.
[3]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[4]	张胥磊, 杨庆余, 韩秋玉, 缪鋆鋆, 蔡仁诚, 马亦旻. 自拟中药治疗非酒精性脂肪性肝病患者血清炎症反应指标水平的变化*[J]. 实用肝脏病杂志, 2019, 22(5): 660-663.
[5]	裴颖, 黄峰, 殷宏振, 郭化磊. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探*[J]. 实用肝脏病杂志, 2019, 22(4): 486-489.
[6]	张兰华, 邵琴, 夏振娟. 非酒精性脂肪性肝病儿童血清25-（OH）D3和IL-17水平变化初步研究^*[J]. 实用肝脏病杂志, 2019, 22(4): 522-525.
[7]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[8]	符亮, 吴冬冰, 纪新尊, 万鸿兴, 李文刚, 饶卉明, 钟静, 江婷婷. 超声定量评估非酒精性脂肪性肝病患者肝脏ARFI值对显著NASH的诊断价值分析[J]. 实用肝脏病杂志, 2019, 22(3): 377-380.
[9]	朱光曦（综述）, 文良志, 陈东风（审校）. 非酒精性脂肪性肝病相关肝细胞癌发病机制研究进展[J]. 实用肝脏病杂志, 2019, 22(3): 453-456.
[10]	霍会芹,巩晓红,李正宏. 采用实时三维超声和斑点追踪技术评价非酒精性脂肪性肝病肝硬化患者右心功能^*[J]. 实用肝脏病杂志, 2019, 22(2): 244-247.
[11]	苏淑婷,钟燕（综述）,宓余强（审校）. 非酒精性脂肪性肝病分级分期管理研究进展[J]. 实用肝脏病杂志, 2019, 22(2): 293-296.
[12]	谢晓（综述）,陆伦根（审校）. 无创诊断和评估非酒精性脂肪性肝炎研究进展^*[J]. 实用肝脏病杂志, 2019, 22(2): 301-306.
[13]	张枫, 阎妍. 非酒精性脂肪性肝病患者血清载脂蛋白B水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(1): 61-64.
[14]	宋娜, 刘晓燕, 刘畅, 山秀杰, 苏东峰, 李丽慧. 非酒精性脂肪性肝病合并2型糖尿病患者血浆促甲状腺激素水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(1): 65-68.
[15]	崔清华, 陶红, 王晓玥, 张凤丽. 非酒精性脂肪性肝病患者血清糖化血红蛋白水平和心功能指标的变化研究^*[J]. 实用肝脏病杂志, 2019, 22(1): 69-72.